Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users.
Laharie D, Droz-Perroteau C, Bénichou J, Amouretti M, Blin P, Bégaud B, Guiard E, Dutoit S, Lamarque S, Moride Y, Depont F, Fourrier-Réglat A, Moore N. Laharie D, et al. Among authors: amouretti m. Br J Clin Pharmacol. 2010 Mar;69(3):295-302. doi: 10.1111/j.1365-2125.2009.03588.x. Br J Clin Pharmacol. 2010. PMID: 20233201 Free PMC article.
Impact of prescriber nonresponse on patient representativeness.
Fourrier-Réglat A, Droz-Perroteau C, Bénichou J, Depont F, Amouretti M, Bégaud B, Moride Y, Blin P, Moore N; CADEUS Team. Fourrier-Réglat A, et al. Among authors: amouretti m. Epidemiology. 2008 Mar;19(2):186-90. doi: 10.1097/EDE.0b013e31816326e9. Epidemiology. 2008. PMID: 18300697
The CADEUS study: methods and logistics.
Depont F, Fourrier A, Merlière Y, Droz C, Amouretti M, Bégaud B, Bénichou J, Moride Y, Blin P, Moore N; CADEUS Team. Depont F, et al. Among authors: amouretti m. Pharmacoepidemiol Drug Saf. 2007 May;16(5):571-80. doi: 10.1002/pds.1348. Pharmacoepidemiol Drug Saf. 2007. PMID: 17121428
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
Depont F, Fourrier A, Merlière Y, Droz C, Amouretti M, Bégaud B, Bénichou J, Moride Y, Velo GP, Sturkenboom M, Blin P, Moore N; CADEUS Team. Depont F, et al. Among authors: amouretti m. Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):891-900. doi: 10.1002/pds.1388. Pharmacoepidemiol Drug Saf. 2007. PMID: 17351983
Predictors of response to infliximab in luminal Crohn's disease.
Laharie D, Salzmann M, Boubekeur H, Richy F, Amouretti M, Quinton A, Couzigou P, Lamouliatte H, Zerbib F. Laharie D, et al. Among authors: amouretti m. Gastroenterol Clin Biol. 2005 Feb;29(2):145-9. doi: 10.1016/s0399-8320(05)80718-3. Gastroenterol Clin Biol. 2005. PMID: 15795662 Free article.
Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate.
Laharie D, Zerbib F, Adhoute X, Boué-Lahorgue X, Foucher J, Castéra L, Rullier A, Bertet J, Couzigou P, Amouretti M, de Lédinghen V. Laharie D, et al. Among authors: amouretti m. Aliment Pharmacol Ther. 2006 Jun 1;23(11):1621-8. doi: 10.1111/j.1365-2036.2006.02929.x. Aliment Pharmacol Ther. 2006. PMID: 16696812
131 results